Centessa Pharmaceuticals (CNTA) Insider Trading & Ownership $16.17 +0.03 (+0.19%) (As of 09:46 AM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.59%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$5.86 M Get CNTA Insider Trade Alerts Want to know when executives and insiders are buying or selling Centessa Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CNTA Insider Buying and Selling by Quarter Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Centessa Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/25/2024Gregory M WeinhoffInsiderSell11,742$15.38$180,591.96 10/23/2024Saurabh SahaCEOSell2,592$15.32$39,709.44 10/21/2024Saurabh SahaCEOSell22,205$15.80$350,839.00 9/25/2024Gregory M WeinhoffInsiderSell16,619$15.69$260,752.11 9/20/2024Saurabh SahaCEOSell55,000$16.53$909,150.00 9/10/2024Saurabh SahaCEOSell175,000$16.52$2,891,000.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/9/2024Gregory M WeinhoffInsiderSell25,000$15.00$375,000.00 8/22/2024Gregory M WeinhoffInsiderSell12,198$12.17$148,449.66 8/22/2024Saurabh SahaCEOSell506$12.23$6,188.38 8/20/2024Saurabh SahaCEOSell4,169$12.32$51,362.08 3/25/2024Karen M AndersonInsiderSell51,160$11.88$607,780.80 2/1/2024Harris RotmanSVPSell4,267$8.10$34,562.70 (Data available from 1/1/2013 forward) CNTA Insider Trading Activity - Frequently Asked Questions Who is on Centessa Pharmaceuticals's Insider Roster? The list of insiders at Centessa Pharmaceuticals includes Aaron Kantoff, Antoine Yver, David J Grainger, David M Chao, Gregory M Weinhoff, Harris Rotman, Iqbal J Hussain, Karen M Anderson, Medicxi Ventures Management (J, Rubertis Francesco De, Saurabh Saha, Thomas Templeman, and Tia L Bush. Learn more on insiders at CNTA. What percentage of Centessa Pharmaceuticals stock is owned by insiders? 11.59% of Centessa Pharmaceuticals stock is owned by insiders. Learn more on CNTA's insider holdings. Which Centessa Pharmaceuticals insiders have been selling company stock? The following insiders have sold CNTA shares in the last 24 months: Antoine Yver ($117,899.60), Gregory M Weinhoff ($964,793.73), Harris Rotman ($270,337.06), Karen M Anderson ($607,780.80), Saurabh Saha ($4,248,248.90), and Tia L Bush ($35,840.00). How much insider selling is happening at Centessa Pharmaceuticals? Insiders have sold a total of 455,612 Centessa Pharmaceuticals shares in the last 24 months for a total of $6,244,900.09 sold. Centessa Pharmaceuticals Key ExecutivesDr. Saurabh Saha M.D. (Age 48)Ph.D., CEO & Director Compensation: $1.04MDr. David M. Chao Ph.D. (Age 56)Chief Administrative Officer Compensation: $710.3kMr. John J. Crowley CPA (Age 50)CFO and Principal Financial & Accounting Officer Ms. Tia L. Bush (Age 53)Chief Technology & Quality Officer Ms. Kristen K. Sheppard Esq.J.D., Senior Vice President of Investor Relations & Corporate CommunicationsMr. Iqbal J. Hussain L.L.B. (Age 43)General Counsel, Chief Compliance Officer & Corporate Secretary Ms. Karen M. Anderson (Age 56)Chief People Officer Dr. Gregory M. Weinhoff M.B.A. (Age 53)M.D., Chief Business Officer Compensation: $655kDr. Mario Alberto Accardi Ph.D.President of the Orexin ProgramMs. April DovholukSenior Vice President of Development Operations More Insider Trading Tools from MarketBeat Related Companies Scholar Rock Insider Transactions Ocugen Insider Transactions Ventyx Biosciences Insider Transactions Repare Therapeutics Insider Transactions Aclaris Therapeutics Insider Transactions Seres Therapeutics Insider Transactions Agenus Insider Transactions Elanco Animal Health Insider Transactions Cytokinetics Insider Transactions Nuvalent Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Here’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics PartnersInsider Selling is not a Signal to Start Selling Gartner Stock This page (NASDAQ:CNTA) was last updated on 11/8/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredJD Vance Exposes Wall Street’s Secret Plot Against TrumpTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
